Sonoran Biosciences is a privately held specialty pharmaceutical company developing sustained release formulations for the treatment of postoperative pain and prevention of surgical site infection.
Our approach is to provide localized, sustained drug delivery directly to surgical sites, providing high and sustained drug levels for multiple days.
Our lead products are SBG004, a local anesthetic for multi-day treatment of postoperative pain, and SBG003, an antimicrobial for prevention of surgical site infection.
About 14 million surgical procedures in the US annually are associated with moderate-to-severe postoperative pain. Patients often experience moderate pain at rest for up to three days and severe pain with basic activities like joint motion or coughing for up to seven days postoperatively. Current recommendations support treatment of postoperative pain using multimodal analgesia, which combines drugs from multiple classes to reduce the need for opioids. Local anesthetics are potent in reducing severe pain by blocking neural conduction from local pain receptors but have a short effective duration (up to 8-12 hr). A sustained-release local anesthetic acting for at least three days would be an ideal foundation for effective multimodal analgesia, safely providing local pain control while minimizing the need for opioids.
Surgical Site Infection
About 5 million procedures in the US annually are at high risk of developing a surgical site infection (SSI). According to the World Health Organization, SSIs are responsible for additional hospital costs of $10 billion in the US and €11 billion in the EU annually. Most SSIs are caused by bacteria present in the surgical site prior to closure despite adherence to best practices including the use of topical antiseptics and systemic antimicrobial prophylaxis. A sustained-release local antibiotic is well-suited to provide high antibiotic concentrations throughout the surgical site for a sufficient time to kill bacteria, reducing the risk of infection.
SB Gel is a proprietary biomaterial ideally suited for localized, multi-day drug release.
Sonoran Biosciences Reports Positive Results for Postoperative Pain Program
Sonoran Biosciences Announces Qualified Infectious Disease Product (QIDP) Designation Granted for SBG003
Sonoran Biosciences has received a Phase 2B SBIR award from the National Institutes of Health for $2 million
Sonoran Biosciences has filed a new patent application on the SB Gel platform